info:eu-repo/semantics/article
Postsurgical Intestinal Rehabilitation Using Semisynthetic Glucagon-Like Peptide-2 Analogue (sGLP-2) at a Referral Center: Can Patients Achieve Parenteral Nutrition and sGLP-2 Independency?
Registro en:
Solar, Héctor; Doeyo, Mariana; Ortega, Mariana; De Barrio, Silvia; Olano, Estela; et al.; Postsurgical Intestinal Rehabilitation Using Semisynthetic Glucagon-Like Peptide-2 Analogue (sGLP-2) at a Referral Center: Can Patients Achieve Parenteral Nutrition and sGLP-2 Independency?; SAGE Publications; Journal of Parenteral and Enteral Nutrition; 45; 5; 8-2021; 1072-1082
0148-6071
CONICET Digital
CONICET
Autor
Solar, Héctor
Doeyo, Mariana
Ortega, Mariana
De Barrio, Silvia
Olano, Estela
Moreira, Eduardo
Buncuga, Martín Gonzalo
Manzur, Alejandra Marisa
Crivelli, Adriana
Gondolesi, Gabriel Eduardo
Resumen
Background: Teduglutide, a semisynthetic analogue of glucagon-like peptide-2 (sGLP-2), increases intestinal absorption of fluids and nutrients, reducing the need for parenteral nutrition (PN). This report aims to describe our experience with sGLP-2 in a cohort of adult patients with short-bowel syndrome. Methods: This is a prospective observational study on adult patients initially evaluated in our specialized intestinal rehabilitation program that received sGLP-2 from June 2014 to March 2020. Results: Autologous gastrointestinal reconstruction surgery (AGIRS) was performed in 108 patients; 68.5% (74 of 108) achieved intestinal sufficiency with standard medical therapy. Seventeen patients were treated with sGLP-2; 66.5% (8 of 12) received treatment for a mean time of 25.8 weeks (3.4–54.0) and could suspend PN. One patient reinitiated treatment due to renal lithiasis and acute renal failure. Currently, 7 of 12 patients (53.8%) continue without PN for a mean time of 165.6 weeks. Volume, energy, and days of PN were reduced in all patients. No serious adverse events were registered. Four of 7 patients (57.1%) who discontinued PN could also discontinue sGLP-2. Therefore, the use of sGLP-2 increased the overall success rate of PN independency after AGIRS to 76% (82 of 108). Conclusion: This study confirmed that sGLP-2 should be considered as part of the standard therapy for postsurgical medical rehabilitation treatment in patients with chronic intestinal failure. We add to the current knowledge that some patients can discontinue both PN and sGLP-2 in the long term, achieving complete recovery of their quality of life. Fil: Solar, Héctor. Universidad Favaloro; Argentina Fil: Doeyo, Mariana. Universidad Favaloro; Argentina Fil: Ortega, Mariana. Universidad Favaloro; Argentina Fil: De Barrio, Silvia. Hospital San Martín; Argentina Fil: Olano, Estela. Hospital Maciel; Uruguay Fil: Moreira, Eduardo. Hospital Maciel; Uruguay Fil: Buncuga, Martín Gonzalo. Delta Hospital; Argentina Fil: Manzur, Alejandra Marisa. Gobierno de la Provincia de Mendoza. Hospital Central de Mendoza.; Argentina Fil: Crivelli, Adriana. Universidad Favaloro; Argentina Fil: Gondolesi, Gabriel Eduardo. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Medicina Traslacional, Trasplante y Bioingeniería. Fundación Favaloro. Instituto de Medicina Traslacional, Trasplante y Bioingeniería; Argentina